Contents xiii
Cannabigerol( CBG) |
392 |
Mechanism of action and clinical application |
392 |
Pharmacokinetics |
393 |
Safety Toxicity |
394 |
Cannabidiol( CBD) |
394 |
Mechanism of action |
394 |
Clinical application |
394 |
Pharmacokinetic s of CBD |
394 |
Published safety and toxicity of CBD |
396 |
Clinical signs of the acute C BD overdose ingestion 396 |
|
▲ 9-Tetrahydrocannabinol( ▲ 9-THC)
396
|
Mechanism of action 396
▲ 9-THC isomers, novel psychoactive substances( NPS), or semi-synthetic cannabinoids 398
Toxicokinectics / Pharmacokinetics of
▲ 9-THC 398 Published safety and toxicity of
▲ 9-THC 399 Published ▲ 9-THC poisoning in other animals 400
Clinical signs in the THC exposure patient 400 A brief discussion on synthetic cannabinoids 400 Reproductive considerations 401 Drug interactions 401 Diagnostic testing 402
Non-specific diagnostics 402
Management and treatment of the poisoned patient 402 General management 402 Intravenous lipid emulsion 402 Extracorporeal therapy 403 Naloxone 403 Prognosis 403 Concluding remarks 403 Acknowledgments 403 References 403
Section E Metals and micronutrients
22. Arsenic
Tam Garland
Introduction 409 Background 409 Pharmacokinetics / toxicokinetics 409 Mechanism of action 410 Toxicity 411 Treatment 411
Concluding remarks and future directions References
23. Cadmium
Stephen B. Hooser
Introduction |
415 |
Background |
415 |
Pharmacokinetics / toxicokinetics |
416 |
Mechanism of action |
416 |
Toxicity 417
Treatment 418
Concluding remarks and future |
directions |
418 |
References |
418 |
24. Chromium, iodine, and phosphorus
Larry /. Thompson
Phosphorus 422 References 422
25. Copper
Larry J. Thompson
Introduction |
423 |
Background |
423 |
Pharmacokinetics |
424 |
Mechanism of action |
424 |
Toxicity 424 Acute exposures 424 Chronic exposures 425
Treatment |
425 |
Concluding remarks and future |
directions |
425 |
References |
425 |
26. Fluoride
Larry J. Thompson
412 412
Introduction |
427 |
Background |
427 |
Pharmacokinetics and mechanism of |
action 428
Toxicity 429 Chronic exposure 429 Acute exposure 429
Treatment 430
Concluding remarks and future directions 430
References 430